Shares of Agenus Inc. (AGEN) are surging more than 25% Tuesday morning after the company granted exclusive global license to Bristol-Myers Squibb Company (BMY) for Agenus' anti-TIGIT bispecific antibody Program, AGEN1777.
Agenus will receive a $200 million upfront payment and up to $1.36 billion, on achieving milestones, in addition to tiered double-digit royalties on net product sales.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.